Citation index
Filip K. Knop, MD, PhD
University of Copenhagen, Center for Clinical Metabolic Research
Physician-scientist whose research addresses incretin physiology, the pathophysiology of type 2 diabetes, and the pharmacological development of GLP-1-based therapies.
Public profiles
Cited on Peptides Research Hub
- Semaglutide: research, pharmacology, and clinical evidence
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The SELECT trial demonstrated cardiovascular risk reduction in people with obesity but without diabetes. This pillar covers mechanism, half-life, pharmacokinetics, pivotal trials, safety, and regulatory status.
- Semaglutide Mechanism of Action: GLP-1 Receptor Agonism
Semaglutide
Semaglutide selectively activates the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. This article explains the receptor pharmacology, downstream signaling, and the structural features that confer DPP-4 resistance and albumin binding.
- Semaglutide Half-Life and Pharmacokinetics
Semaglutide
Semaglutide's mean terminal half-life is approximately 165 hours. This article covers the Aib8 substitution, C18 fatty diacid albumin-binding strategy, oral bioavailability with the SNAC enhancer, dose titration for Ozempic and Wegovy, and special-population pharmacokinetics.
- Semaglutide Safety Profile and Adverse Events
Semaglutide
This article summarizes adverse events from semaglutide's pivotal programs, the boxed warning for thyroid C-cell tumors, gastrointestinal event frequencies, pancreatitis, gallbladder disease, the retinopathy worsening signal from SUSTAIN-6, post-marketing suicidal ideation review, and considerations in pregnancy and lactation.